72
Participants
Start Date
January 20, 2023
Primary Completion Date
January 31, 2026
Study Completion Date
August 30, 2027
Vorasidenib
Administered orally as tablets.
Pembrolizumab
Administered as IV infusion.
RECRUITING
Memorial Sloan Kettering Cancer Center (Site: 840117), New York
RECRUITING
University of Pennsylvania Health System, Philadelphia
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
Duke University (Site: 840110), Durham
RECRUITING
University of Miami (Site: 840129), Miami
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Mayo Clinic Florida, Cleveland
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Northwestern University (Site: 840123), Chicago
RECRUITING
MD Anderson Cancer Center (Site: 840102), Houston
RECRUITING
University of Colorado, Aurora
RECRUITING
University of Utah, Huntsman Cancer Center, Salt Lake City
RECRUITING
University of California, Los Angeles (Site: 840113), Los Angeles
RECRUITING
University of California, San Francisco (Site: 840149), San Francisco
RECRUITING
Massachusetts General Hospital (Site: 840104), Boston
RECRUITING
Dana-Farber Cancer Institute (Site: 840139), Boston
Merck Sharp & Dohme LLC
INDUSTRY
Institut de Recherches Internationales Servier
OTHER